BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Spencer Technologies' Mark Moehring, Ph.D. To Present Embolus Characterization Data At Summer In Seattle


10/19/2005 5:08:57 PM

SEATTLE, July 19 /PRNewswire/ -- Spencer Technologies announced today that Mark Moehring, Ph.D. will present his recent results of Embolus Characterization Using Harmonic Doppler on Wednesday, July 21st at the Emerging Technologies Symposium, which is part of the Summer in Seattle Interventional Cardiac and Vascular Therapies Course.

Dr. Moehring is using Spencer Technologies' digital Power M-Mode Doppler (PMD) to characterize microemboli as gaseous or solid (formed element). Microemboli can potentially obstruct blood flow, at least temporarily, in the terminal branches of arteries and/or in the microcirculation. Microemboli have also been associated with stroke, heart attacks, peripheral arterial diseases, deep venous thrombosis which can result in pulmonary embolism, and procedures such as cardiovascular surgery and catheterizations.

Characterizing microemboli can be important for clinical management of patients when the source underlying cause is ambiguous. Utilizing PMD to differentiate microembolus composition is projected to be a vital tool in determining when and which therapies are appropriate.

"A national forum like Summer in Seattle is a great venue to hear valuable critique, as well as stimulating discussion on technologies in their early stages," stated Dr. Moehring, V.P. of Research & Development at Spencer Technologies.

About Mark Moehring, Ph.D.

Dr. Moehring is the V.P. of Research & Development at Spencer Technologies, and is a co-inventor of the Company's patented Power M-Mode Doppler (PMD) technology. He is also an affiliate Assistant Professor in the Bioengineering Department at the University of Washington in Seattle and has over 20 years experience in Doppler ultrasound engineering for a number of cardiovascular applications. Dr. Moehring was formerly a senior scientist at the Institute of Applied Physiology and Medicine (IAPM) in Seattle.

About Spencer Technologies

Spencer Technologies was co-founded in 1992 by Dr. Merrill Spencer, a pioneer in the development of diagnostic ultrasound. Spencer Technologies is dedicated to preventing a variety of adverse cardiovascular related events, including strokes, and significantly improving healthcare through the development and use of non-invasive ultrasound technologies for diagnosis, monitoring, and therapeutic effects. Spencer Technologies is involved in all aspects of ultrasound through integrated patient services, clinical research, R & D, manufacturing, and marketing their products and services.

Spencer Technologies

CONTACT: Gail Kinner, Sales & Marketing Manager of Spencer Technologies,+1-206-329-7220, or gail@spencertechnologies.com


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->